Company intelligence / Profile preview

Ray Capital

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Ray Therapeutics is advancing optogenetic gene therapies to restore vision in patients with inherited retinal degenerative diseases. Lead program RTx-015 (previously Ray-001) for retinitis pigmentosa is supported by preclinical data and plans first-in-human trials within 12 months of 2023 funding.

Therapeutic areas: Ophthalmology
Modalities: Gene therapy
Industry: Biotech

Partnerships

California Institute for Regenerative Medicine (CIRM)

Beyond the preview

Go deeper on Ray Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ray Capital.

Explore the full profile